KRRO
Korro Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.35
−12.29%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$11.71
From 52W high−79.85%
Volume590920.00
Market cap$152.41M
P/E (TTM)—
P/S (TTM)64.0x
Div yield—
Key dataSep 18, 2026
Open
$11.71
From 52W high
−79.85%
Volume
590920.00
Market cap
$152.41M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
P/E (TTM)
—
RSI (14)
33.1
MomentumView details →
1D Return
−12.29%
YTD Return
+26.59%
SummaryUpdated Jun 1, 2026
Korro Bio, Inc. (NASDAQ:KRRO) is a biopharmaceutical company founded in 2018 and headquartered in Cambridge, Massachusetts. The company went public in October 2019 and specializes in developing genetic medicines through RNA editing technology. Korro Bio focuses on creating treatments for both rare genetic diseases and more common conditions by correcting disease-causing mutations at the RNA level rather than permanently altering DNA. The company is currently in the clinical development stage with multiple programs targeting various therapeutic areas.
Similar companies
Latest newsMore news →
Korro Bio nominated KRRO-111 as a development candidate for the treatment of Alpha-1 Antitrypsin Deficiency.45d agoKorro Bio, Inc. exchanged 1,000,000 outstanding common shares for pre-funded warrants to purchase 1,000,000 new shares of common stock, with an exercise price of $0.001 per share, in a transaction with Venrock Healthcare Capital Partners entities on August 6, 2026.46d ago